SCHEMBL14804182

SCHEMBL14804182

CC(C)(C)[Si](C)(C)OCCOc1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.51
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
SLC2A1 P11166 1/20 0.45
HTT P42858 1/20 0.44
KCNH2 Q12809 1/20 0.44
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14804187 0.92 L3MBTL1 (0.49) L3MBTL1RAB9ANPC1MAPTHPGD
SCHEMBL14804186 0.82 L3MBTL1 (0.45) L3MBTL1RAB9AMAPTHPGDHTT
SCHEMBL20900528 0.82 TDP1 (0.44) L3MBTL1RAB9ANPC1MAPTHPGD
SCHEMBL12634859 0.81 DUT (0.37) L3MBTL1MAPTHPGDTDP1HTT
SCHEMBL3056560 0.81 CYP1A2 (0.53) MAPTTDP1HTTCYP1A2CYP2C19
SCHEMBL1927440 0.81 HTR7 (0.50) L3MBTL1RAB9ANPC1MAPTHPGD
SCHEMBL30375395 0.81 DUT (0.37) L3MBTL1MAPTHPGDTDP1HTT
SCHEMBL14804133 0.80 MAPT (0.50) L3MBTL1RAB9ANPC1MAPTHPGD
SCHEMBL5240512 0.79 ALDH1A1 (0.39) L3MBTL1RAB9AMAPTHPGDTDP1
SCHEMBL9808263 0.78 L3MBTL1 (0.68) L3MBTL1RAB9ANPC1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 L3MBTL1 1136/4885RAB9A 2257/4885NPC1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.